Abstract: In certain aspects, disclosed herein are methods of treating cancer in a subject, comprising administration to the subject of (1) one or more glucocorticoid receptor agonists and (2) one or more inhibitors of calcineurin. In some embodiments, the administration of the one or more glucocorticoid receptor agonists and the one or more inhibitors of calcineurin results in restoration of contact inhibition, increased formation of intercellular junctions, reduced cell proliferation, and/or increased vacuolization of cells growing in multilayer zones. Included herein are methods for identification of novel compounds that restore contact inhibition in cancer cells.

Abstract: Described herein are methods useful for the treatment of cancers in a canine subject with a pharmaceutical compositions comprising HDAC inhibitors, Rapamycin, Dasatinib, Lapatinib, Trametinib, Vorinostat, Imatinib, Crizotinib, Sorafenib, and combinations thereof. Also described herein are methods for identification of subjects with cancers that will benefit from administration of the pharmaceutical compositions comprising HDAC inhibitors, Rapamycin, Dasatinib, Lapatinib, Trametinib, Vorinostat, Imatinib, Crizotinib, Sorafenib, and combinations thereof. In certain aspects, the methods described herein further comprise administering a therapeutically effective amount of at least one additional anti-cancer agent.

Abstract: Described herein are methods useful for the treatment of cancers in a canine subject with a pharmaceutical compositions comprising HD AC inhibitors, Rapamycin, Dasatinib, Lapatinib, Trametinib, Vorinostat, Imatinib, Crizotinib, Sorafenib, and combinations thereof. Also described herein are methods for identification of subjects with cancers that will benefit from administration of the pharmaceutical compositions comprising HD AC inhibitors, Rapamycin, Dasatinib, Lapatinib, Trametinib, Vorinostat, Imatinib, Crizotinib, Sorafenib, and combinations thereof. In certain aspects, the methods described herein further comprise administering a therapeutically effective amount of at least one additional anti-cancer agent.